Life Sciences & Medicine Active Updated Nov 21, 2026

Is there a treatment for Alzheimer's yet?

The many-fronted fight against Alzheimer's

Where it stands as of Nov 16, 2026

The work now spans many fronts: how tau spreads, drugs that retune the brain's immune cells, blood tests and scans that catch the disease early, the blood-brain barrier, and gene maps. The largest genetic scan yet, in more than 2.8 million people, found 127 risk regions, 48 of them new, with signals pointing at the brain's immune cells. A genome scan finds associations, not causes, so none of those regions is yet a treatment target proven in people.

0 of 1 promise kept, 1 still open

Researchers are attacking Alzheimer's from several directions at once: the biology of how it spreads, drugs that reprogram the brain's immune cells, and blood tests that could catch it years early.

The story so far

  1. Nov 21, 2026 Latest

    Psychiatric Times reported that the drug emestedastat fell short overall in an Alzheimer's trial but signaled benefit in a subgroup. Separately, a Cambridge review linked reading for pleasure to a 33 percent lower Alzheimer's risk, an association rather than a proven cause.

    Today Got Better

  2. Nov 19, 2026

    University of Sydney researchers delivered mRNA for the growth factor BDNF through the nose, and 18-month-old mice then performed like young ones on memory tests. It has not been tested in people.

    Today Got Better

  3. Nov 16, 2026

    An international genetic study in Nature, covering more than 2.8 million people, identified 127 DNA regions associated with Alzheimer's disease, 48 of them new, and found common inherited variants explain nearly three times as much of the variation in risk as earlier estimates. The results link genetic risk to heightened gene activity in the brain's immune cells and dampened activity in nerve cells. Separately, ScienceAlert reported that in nearly 165,000 adults 65 and older, a high-dose flu shot was tied to up to 22 percent lower Alzheimer's risk over two years than a standard dose, an association that cannot prove cause and effect.

    Today Got Better

  4. Nov 15, 2026

    Johns Hopkins researchers reported in NeuroImage Reports that the entorhinal cortex and amygdala begin losing tissue before the hippocampus, tracking with abnormal tau buildup, a window senior author Michael Miller put at at least 5 to 10 years. Separately, Stanford's resting-state fMRI ARC score predicted decline in 1,315 unimpaired adults better than demographics, genetic risk, and amyloid and tau biomarkers. Both are scan patterns, not diagnoses or treatments.

    Today Got Better

  5. Nov 13, 2026

    Gladstone Institutes researchers led by Andrew Yang tracked 861 blood proteins in mice and found the blood-brain barrier imports just 92 of them, mostly from the liver. In mouse models of Alzheimer's, the barrier stopped importing protective proteins such as APOA1 before it began leaking toxins, and boosting APOA1 in the blood restored neuronal connectivity and halted disease progression in those animals. Nature's daily briefing flagged the same work. It was done in mice only.

    Today Got Better

  6. Nov 11, 2026

    Neuroscience News reported that a University of Virginia team led by John Lukens found the Alzheimer's risk gene CASS4 works inside microglia, not neurons as assumed, letting them surround amyloid-beta plaques and pack them into compact clusters. When CASS4 was impaired in preclinical models, plaques spread, synapses were destroyed and cognition declined quickly. Nature separately profiled geneticist Henne Holstege's work on people who stay dementia-free despite high risk, including carriers of rare protective ApoE variants.

    Today Got Better

  7. Nov 10, 2026

    ScienceDaily reported that University of Central Florida researchers James Hickman and Xiufang Guo put inherited Alzheimer's mutations into human motor neurons in lab-built systems and found the nerve-to-muscle connections were disrupted with no brain or spinal cord present. The work, published in Alzheimer's & Dementia, points to a possible early movement signal in the rare familial form, but it is cell work and does not show that movement tests catch anyone earlier.

    Today Got Better

  8. Nov 9, 2026

    ScienceDaily reported that UTHealth Houston researchers analyzed nearly 200,000 adults aged 65 and older and found the high-dose flu vaccine went with a nearly 55% lower Alzheimer's risk than the standard dose, against a 40% reduction linked to the standard shot in earlier work. New Scientist separately reported University of Sydney work on 22,618 UK Biobank adults in which about 3.7 minutes a day of vigorous routine movement went with a 48% lower dementia risk. Both are observational and cannot show cause.

    Today Got Better

  9. Nov 8, 2026

    ScienceDaily reported a long-running U.S. study with up to 43 years of follow-up in which people who drank the most caffeinated coffee developed dementia at 141 cases per 100,000 a year, against 330 among people who rarely or never drank it, with the best results at two to three cups a day. ScienceAlert separately reported UK Biobank data on nearly 88,000 older adults in which at least 42 minutes a day of bright light went with a 17 percent lower relative risk of dementia about eight years later. Both are associations, not trials.

    Today Got Better

  10. Nov 7, 2026

    PsyPost reported a PNAS study using UK Biobank data and Britain's 1972 rise in the school-leaving age from 15 to 16, which found the extra year of schooling reduced early dementia diagnoses and narrowed the gap between people at high and low inherited risk. A 2020 study of 1.3 million Swedish adults, looking at a different school reform, found almost no effect on dementia diagnoses.

    Today Got Better

  11. Nov 4, 2026

    PsyPost reported that Salk researchers searched 610 brain samples and found 1,067 previously uncataloged microproteins with strong evidence of existing, many of them altered in Alzheimer's disease.

    Today Got Better

  12. Nov 3, 2026

    New Scientist reported that Vesa Kiviniemi's team at the University of Oulu gave 29 adults without Alzheimer's a nitric oxide pill under the tongue and 40 minutes on a gently vibrating mattress, and blood beta-amyloid 42 rose by 35 percent on average. This is a sign that protein is leaving the brain through the glymphatic system, but it was one session in healthy people. ScienceDaily separately reported that in older rats two weeks of the experimental drug cinaciguat halved amyloid beta and returned LDL cholesterol to youthful levels; it has not been tested in people.

    Today Got Better

  13. Nov 2, 2026

    PsyPost reported an analysis of autopsy records for 2,959 women in which the 258 who had used estrogen-only hormone therapy were less likely to show advanced Alzheimer's pathology, and also showed fewer signs of cerebrovascular disease. The result is observational, so it points a direction without showing that the therapy caused the difference.

    Today Got Better

  14. Nov 1, 2026

    ScienceDaily reported that Mass General Brigham researchers pooled six studies covering 2,684 older adults with no cognitive impairment and measured blood p-tau217 at baseline. In JAMA, they found that people with very high p-tau217 had a 38% risk of developing cognitive impairment within five years and an estimated 78% within ten, though the ten-year figure rests on much less data. About 478 participants eventually developed impairment, and the result describes risk in the highest group, not a diagnosis.

    Today Got Better

  15. Oct 31, 2026

    Psychiatric Times reported that sabirnetug missed its primary endpoint in a Phase 2 Alzheimer disease trial. It also covered a mouse study in which administering the tuberculosis vaccine was linked to reduced tau burden.

    Today Got Better

  16. Oct 28, 2026

    ScienceDaily reported that Evgenia Salta's team at the Netherlands Institute for Neuroscience studied a rare group of immature neurons that are still present in people over 80. The cells behave differently in people who develop dementia than in those who stay cognitively healthy. Salta noted that around 30 percent of older adults who develop Alzheimer's never experience its symptoms. Finding immature neurons does not prove they were recently formed, so the result is a clue about resilience and not a treatment.

    Today Got Better

  17. Oct 24, 2026

    NIH reported that University of Wisconsin-Madison and University of Southern California researchers used Britain's 1972 rise in the school-leaving age from 15 to 16 as a natural experiment in more than 100,000 UK Biobank participants. The extra year of school lowered Alzheimer's and related dementia incidence over the following 50 years by .88%, with the biggest benefit in people carrying genetic variants that raise risk. The diagnoses counted run only to December 2022, and the study does not separate the classroom from the life that followed it.

    Today Got Better

  18. Oct 21, 2026

    Washington University in St. Louis researchers gave tau-burdened mice an antibody blocking CXCR3, a protein that helps T cells enter the brain. T cells in the brain fell by about half, and treated mice kept roughly 40 percent more tissue in memory regions and did better on a memory test, though tau levels did not change. Separately, an eLife team's human forebrain organoids showed microglia clearing amyloid-beta while also recruiting CD8+ T cells through CCL4/5 signaling, and drugs blocking CCR5 or CXCR3 stopped that recruitment.

    Today Got Better

  19. Oct 20, 2026

    A Nature Aging paper with Caghan Kizil as corresponding author showed that a rare FN1 mutation found in resilient APOE4 carriers protects the blood-brain barrier. In mice carrying human APOE4, fibronectin around brain vessels ran at nearly twice the level in APOE3 mice, and raising it made the barrier leak. ScienceDaily also reported that removing most microglia in Alzheimer's-model mice restored more than two hours of sleep a day without clearing plaques, and Live Science reported that MIT's Li-Huei Tsai found switching off DKK1 reduced the fat droplets APOE4 builds up in oligodendrocytes.

    Today Got Better

  20. Oct 17, 2026

    Neuroscience News reported that MIT researchers traced how the APOE4 variant traps fats in oligodendrocytes, and a compound that inhibits GSK3b dissolved the droplets and restored myelination in human brain organoids and Alzheimer's mice. Gladstone scientists separately found that gamma waves come from brain cells firing in relays, with one-third staying silent, and that restoring the Nav1.1 channel repaired the timing and rescued cognition in Alzheimer's mice. Nature also reported that the enzyme Pla2g2f is linked to preserved memory in resilient aging brains.

    Today Got Better

  21. Oct 15, 2026

    ScienceDaily reported that scientists may have overlooked a hidden culprit in Alzheimer's disease for decades.

    Today Got Better

  22. Oct 14, 2026

    New Atlas reported on research suggesting water could be key to understanding the tangled protein structures in Alzheimer's. Neuroscience News separately reported that PCOS/PMOS is linked to increased Alzheimer's risk.

    Today Got Better

  23. Oct 8, 2026

    Psychiatric Times reviewed the first FDA-cleared Alzheimer's blood test, reporting that it rules the disease out about 97% of the time and confirms amyloid about 92% of the time. Severe kidney failure is the main confounder that can throw it off.

    Today Got Better

  24. Oct 7, 2026

    A neurotoxicologist and colleagues reported in npj Dementia that the aging dog brain changes in ways similar to a human brain with dementia. Canine cognitive dysfunction affects more than a quarter of dogs over age 12, and the team compared brains of affected dogs with those of people with Alzheimer's, using samples donated by owners.

    Today Got Better

  25. Oct 6, 2026

    Birmingham researchers reported that blocking the P2X7 receptor stopped inflammatory cytokine release in living human brain slices taken during neurosurgery. Drugs that block P2X7 have already been through clinical testing, but the work is in tissue, not patients.

    Today Got Better

  26. Oct 2, 2026

    Two Mount Sinai studies, in Cell and Cell Stem Cell, reported that in carriers of the APOE4 gene, pericytes around small brain blood vessels turned into scar-laying myofibroblast-like cells, causing vessel fibrosis and more amyloid buildup. Blocking TGF-β signaling restored pericyte coverage and reduced fibrosis and amyloid, including in aged APOE4 mice, and the second paper described a stem-cell-derived human brain tissue platform for faster drug testing.

    Today Got Better

  27. Oct 1, 2026

    Nature and ScienceAlert reported that harmful tau spreads like a self-propagating prion protein, with ScienceAlert describing the Alzheimer's protein behaving as a prion does in mouse brains.

    Today Got Better

  28. Sep 30, 2026

    David Holtzman's group at Washington University in St. Louis reported in Neuron that an antibody blocking the T cell receptor CXCR3 cut brain-infiltrating T cells by roughly half in mice with Alzheimer's-like tau pathology. Treated mice kept about 40% more tissue in their memory centers and did significantly better on memory tests, while their tau tangles stayed at the same level.

    Today Got Better

  29. Sep 26, 2026

    PsyPost reported a study found midlife belly fat was linked to elevated Alzheimer's biomarkers decades later.

    Today Got Better

  30. Sep 25, 2026

    A study found brain structure changes appeared up to seven years before Alzheimer's-related plaques could be detected, PsyPost reported.

    Today Got Better

  31. Sep 24, 2026

    A study found Alzheimer's-related proteins could predict early brain shrinkage before dementia symptoms appeared, PsyPost reported.

    Today Got Better

  32. Sep 23, 2026

    The World Alzheimer Report 2026 described the disease shifting from something doctors could only watch to something they might interrupt, citing drugs including donanemab and lecanemab and noting more than a third of pipeline candidates were originally developed for other conditions.

    Today Got Better

  33. Sep 16, 2026

    A mouse study found a nasal spray derived from human placenta protected against Alzheimer's-related cognitive decline, ScienceAlert reported.

    Today Got Better

  34. Sep 14, 2026

    A Carnegie Mellon, University of Pittsburgh and University of Washington team used a technique called GAGE-seq on postmortem prefrontal cortex tissue to show that the genome's three-dimensional folding pattern is disrupted in several types of brain cells affected by Alzheimer's, identifying genome architecture as a regulatory layer distinct from amyloid and tau.

    Today Got Better

  35. Sep 6, 2026

    UC San Francisco researchers led by Meri Okorie and Shea J. Andrews built a multi-ancestry Alzheimer's polygenic risk score using genetic data from hundreds of thousands of people of European, African, Admixed American, East Asian and Caribbean Hispanic descent, and found it predicted Alzheimer's diagnosis more accurately across every group than a Europe-only score while also tracking the underlying brain damage the disease causes.

    Today Got Better

  36. Sep 1, 2026

    A University of South Carolina team built a molecular cage that delivers an antibody into astrocytes to release a protein brake holding their identity in place, converting astrocytes into firing neurons in lab dishes and human brain organoids, and in an Alzheimer's mouse model the treatment grew new neurons in the hippocampus and brought treated mice to healthy-mouse performance on memory maze tests.

    Today Got Better

  37. Aug 30, 2026

    A Mount Sinai-led team mapped 830,000 brain immune cells from 1,607 donors and identified a microglia subtype that expands to actively fight Alzheimer's disease as it progresses, giving future treatments a defense system to strengthen instead of only plaques to attack.

    Today Got Better

  38. Aug 24, 2026

    The FDA approved C2N Diagnostics' PrecivityAD2 blood test, the first cleared for symptomatic Alzheimer's patients as young as 40, which correctly identified 97.6 percent of positive amyloid and tau biomarkers in a validation study of 1,142 symptomatic adults and held up even in people with kidney disease or diabetes.

    Today Got Better

  39. Aug 11, 2026

    Nautilus reported that a 2024 study of nearly 9 million US death certificates found taxi and ambulance drivers, who rely on continuous real-time navigation rather than fixed routes, had the lowest Alzheimer's death rate of 443 occupations, about 1 in 100 versus 1 in 60 in the general population, echoing earlier findings that London cabbies who memorized the city's street layout developed measurably more gray matter in the hippocampus.

    Today Got Better

  40. Aug 1, 2026

    New Scientist reported that thousands of people in China have received a lymphatic drainage surgery for Alzheimer's that remains banned in most countries, after small safety trials in the US and Singapore found it safe for up to six months with some signs of cognitive improvement, and a randomized trial against a sham procedure is now underway to test whether it actually works.

    Today Got Better

  41. Jul 27, 2026

    A VIB, KU Leuven, UK Dementia Research Institute and Muna Therapeutics team, publishing in Nature Medicine, compared brain tissue from people with dementia, cognitively healthy older adults, and cognitively healthy centenarians and found some centenarian brains carried heavy amyloid and tau pathology without memory loss. Co-senior author Bart De Strooper's team traced the difference to microglia shifting into distinct protective states in the resistant brains.

    Today Got Better

  42. Jul 25, 2026

    Buck Institute researchers led by Lisa Ellerby engineered human stem cell-derived neurons differing only in APOE genotype and found APOE2 neurons accumulated less DNA damage, switched on DNA repair pathways more strongly, and resisted cellular senescence, with aged mice carrying the human APOE2 gene showing the same pattern in hippocampal tissue.

    Today Got Better

  43. Jul 21, 2026

    A University of Kentucky team led by Shannon Macauley and Nicholas Constantino found that in mice with amyloid plaques, sleep loss traces not to the plaques themselves but to microglia triggering broad brain inflammation while clearing them. Temporarily depleting the microglia restored more than two hours of deep, slow-wave sleep a day without clearing any plaques.

    Today Got Better

  44. Jul 19, 2026

    KCL-286, a drug already proven safe in human Phase 1 trials for a different condition, repaired DNA damage and cut inflammation in a mouse model of Alzheimer's, targeting the disease at a stage before amyloid plaques even form.

    Today Got Better

  45. Jul 15, 2026

    A study led by Kaley Hayes at the University of Massachusetts found older adults recently discharged from skilled nursing facilities who received the recombinant shingles vaccine Shingrix had a lower rate of new dementia diagnosis over four years, enough to estimate the shot could prevent roughly one in 17 cases. The effect builds on an older, discontinued shingles vaccine that showed the same signal, and on the idea that shingles itself inflames the brain and raises stroke risk.

    Today Got Better

  46. Jul 11, 2026

    A University of Kansas Medical Center study found Alzheimer's patients who took daily creatine for two months showed measurable increases in brain energy levels and cognitive test scores, testing the idea that refueling neurons running low on cellular energy helps alongside existing plaque-targeted treatments.

    Today Got Better

  47. Jul 8, 2026

    A Monash University team treated an Alzheimer's mouse model with a copper compound called Cu(ATSM) for 56 days and found P-glycoprotein pump abundance at the blood-brain barrier rose 24.1 percent, amyloid-beta in the brain dropped 42 percent, and spatial learning improved by nearly 44 percent. The approach targets the brain's own waste-clearance system rather than attacking toxic proteins directly. Cu(ATSM) has already been tested in human clinical trials for Parkinson's disease and ALS, giving it an unusual head start on safety evaluation.

    Today Got Better

  48. Jul 7, 2026

    Mass General Brigham researchers confirmed for the first time in humans that the BCG tuberculosis vaccine can cross the blood-brain barrier into cerebrospinal fluid. In healthy older adults without existing Alzheimer's pathology, BCG shifted amyloid-beta levels downward in cerebrospinal fluid while raising them in the bloodstream, suggesting the vaccine helped push the protein out of the central nervous system. The protective shift was absent in participants who already had established Alzheimer's biomarkers, indicating timing is critical.

    Today Got Better

  49. Jul 2, 2026

    Scientists identified a set of circulating RNA molecules in the blood that flagged Alzheimer's onset two to four years before symptoms appeared.

    Today Got Better

  50. Jun 30, 2026

    A University of Utah team showed Alzheimer's spreads tau using the brain's own transport system via the Arc protein, and that blocking Arc cut the spread by about 99 percent in mice.

    Today Got Better

  51. Jun 20, 2026

    Researchers reported a molecule that reprograms the brain's own immune cells, the microglia, to restore their protective function against Alzheimer's damage.

    Today Got Better

  52. Jun 18, 2026

    A study from Niigata University found that APP, the protein most often blamed for Alzheimer's, also acts as a cellular cleaner that protects neurons, complicating the simple plaque story.

    Today Got Better

On the record

The checkable promises in this story, dated the day they were made. A promise is marked kept, slipped or partly met only when a later report says so; past its own date with no report, it reads "no word", which is what silence honestly is.

Pending Jul 2, 2026

Promising Alzheimer's drugs can slow progression when started early, but the infrastructure for population-scale screening does not yet exist.

Reporting in the Today Got Better brief

several promising Alzheimer's drugs have shown they can slow progression when started early, but the clinical infrastructure for population-scale screening does not exist yet

Today Got Better

This story moves with the morning letter.

When this question gets a new answer, the page above changes the same morning. Each morning's letter brings the day's progress in science, medicine and beyond. Free, every day.